Fig. 4From: Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept studyChange from baseline in hepatic fat fraction (A) and body fat distribution (B, C and D) during the study in individual patients. Legend shows the patient number to link individual data from different figuresBack to article page